Leading M&A at a top-5 global CDMO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Quick, Executive Vice President, Corporate Development at Recipharm. In the decade that Mark and Raman have known each other, Mark has risen from a BD role in a small Swedish CMO, to becoming one of the key leaders in a business that has transitioned into becoming one of the top global CDMOs, where Mark has spearheaded the M&A deals. A graduate in Industrial Studies, Mark also did an MBA before joining Recipharm in 2006. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest (and a whole loaf more) with Mark as he explains what it’s been like growing a company from 600 - 9000 people, lifting the lid on CDMO M&A deals (having done 20+ transactions over the past 14 years), who gets involved, red flags to look out for and when you just know it’s a good fit. Mark explains how investing in relationships, embracing diversity and being open to new connections has helped him propel his career in the outsourcing space. He speaks about COVID-19 and how it has impacted a global CDMO in its different phases, including the operational impact of having sites in India and Italy. Lastly, Mark and Raman discuss continued consolidation in the sector and the increasing demand for sterile drug products with supply constraints and COVID-19 vaccines jumping the line.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.